Background Although literature demonstrates a decreased risk of Alzheimer's disease (AD) in individuals with various
Introduction
The relationship between age-related neurodegenerative diseases and cancer remains an important and ongoing area of research as well as clinical interest. Abnormal cancer patterns were first described in patients with Parkinson's disease (PD) where an inverse relationship was determined for PD subsequent to diagnosis of selective types of cancer. 1 This prompted investigation into other neurodegenerative conditions, and several large cohort studies have now demonstrated an inverse association between Alzheimer's disease (AD) and various types of cancer. [1] [2] [3] Analysis of the cognition cohort in a cardiovascular health study demonstrated that individuals with cancer had up to 43% lower risk of subsequent diagnosis of AD (P = 0.02) and those with AD had a 69% decreased risk for subsequent diagnosis of incident cancer. 3 The Framingham Heart Study also demonstrated that participants with a history of cancer had a lower risk of incident AD and vice versa. 2 The bidirectional nature of the relationship between cancer risk and AD risk additionally suggests it is unlikely that the association could be due to bias in study design or population studied. Of interest, the relationship between AD and skin cancers remains less well-elucidated to date. Analysis of data from the Einstein Aging Study (a US East Coast population-based longitudinal study) demonstrated that individuals older than 70 years with non-melanoma skin cancers (NMSC) have significantly reduced risk of subsequent diagnosis of AD compared to individuals without NMSC. 4 Another study evaluating the registry data of a large Danish patient population (16 221 NMSC patients and 1 081 097 matched controls) demonstrated NMSC to be associated with 2-10% reductions in both AD and allcause dementia. 5 As the relationship between MM and AD has not been well-characterized, we searched the data repository for a large, single-centre, urban, US Midwestern patient population to characterize the relationship for both malignant melanoma (MM) and NMSC (squamous cell cancers (SCC) and basal cell cancers (BCC)) with a subsequent diagnosis of AD.
Materials and methods
The Northwestern Medicine Enterprise Data Warehouse (NMEDW), a repository of Electronic Medical Record (EMR) data for over 5 million patients, was searched. The study population consisted of patients who had a first in-clinic encounter between January 2001 and December 2015. Inclusion criteria were age ≥60 and ≤89 years at the time of study entry (first inclinic encounter); follow-up of at least 1 year (defined as the time between the first and last in-clinic encounter); and no diagnosis for AD, MM or NMSC at the time of the study entry. Data collected included age, gender, race and duration of followup. MM and NMSC were detected by ICD-9 codes (MM: 172.0-172.9, BCC: 173.01-173.91 and SCC: 173.02-173.92) and ICD-10 codes (MM: C43.0-C43.9, BCC and SCC: C44.0-C44.9). Incident diagnosis of AD was also detected by ICD-9 and ICD-10 codes (331.0 and G30.0, G30.1, G30.9 respectively), and data were included only if the diagnosis of AD occurred at least 1 year after the index date (MM or NMSC diagnosis or in-clinic encounter). Data on cerebrovascular disease, peripheral vascular disease and diabetes were also collected as potential confounding factors for AD using ICD-9-CM and ICD-10 coding algorithms for Charlson comorbidities. 6 
Statistical analyses
Logistic regression analysis was used to determine the odds ratio (OR) for an association between MM, BCC, SCC and AD. The dependent variable was AD. Multivariable logistic regression was used to adjust analyses for potential confounders including age, gender, race, cerebrovascular disease, peripheral vascular disease and diabetes.
Results
Data for a total of 82 925 patients, age range 60-88 years, with known race, gender and at least 1 year of in-clinic follow-up, were extracted and included for analysis. Of 1147 patients who were diagnosed for MM, five were diagnosed with subsequent AD. Of 2506 who were diagnosed with BCC, five had a subsequent AD diagnosis, and of 967 who were diagnosed with SCC, only one had a subsequent diagnosis for AD (Table 1) . Notably, after adjusting for confounding factors (race, gender, age, cerebrovascular disease, peripheral vascular disease and diabetes), Table 2 .
Discussion
The findings in this study revealed a significantly decreased risk of both a diagnosis of AD in patients with MM and a diagnosis of AD in those with NMSC. Nevertheless, these findings in MM patients are consistent with several large cohort studies reporting lower rates of AD in patients with various other cancer types. 2, 3 Moreover, the finding of decreased diagnoses of AD in those with NMSC remains consistent with prior studies that demonstrate an inverse association between the two conditions. 4, 5 Both biological and psychosocial mechanisms have been proposed to account for the inverse association between NMSC and AD. Physical activity has been shown to provide neuroprotective effects, and physically active persons are at lower risk of developing certain types of dementia. 7 However, outdoor physical activity increases exposure to UV radiation, a well-known risk factor for NMSC. White et al. 4 suggested that NMSC could be a marker for other factors, such as education and socioeconomic status. Lower education may result in decreased reporting of mental illness, whereas higher education may result in more frequent skin checks. As such, lifestyle and psychosocial variables conceivably could account for a relative increase in NMSC and decrease in dementia. Schmidt et al. 5 additionally noted the role of bias in that NMSC may be reported and/or detected less in persons with cognitive impairment, whereas physicians may not be as likely to diagnose dementia in cancer patients given the priorities for patient management.
Signalling pathways involved in cell survival have also been postulated to play a role in the relationship between AD and cancer. Pathways that promote survival (decreased regulation, increased proliferation) are a pro-cancer phenotype, whereas pathways with increased cell death may be a pro-AD phenotype (increased neuronal loss).
Polymorphisms in the p53 tumour suppressor gene are one specific example; inactivation results in higher rates of cancer, whereas mice expressing a constitutively activated p53 have been shown to have accelerated ageing and shorter lifespan, but also low to non-existent rates of cancer. 8, 9 Another possible mechanism involves Pin1, an enzyme involved in protein folding and cell cycle control. Pin1 is overexpressed in many tumours, but has low function in the brain tissue of those with AD. Inhibition of Pin1 can cause tumour regression and decreased risk of cancer, but with an increased risk of AD. Conversely, upregulation in mouse models reverses neurodegeneration. 2, 9, 10 Limitations of this study include inability for verification of diagnostic coding and documentation of diagnosis beyond original medical record data entry. Additionally, MM risk factor data such as that for other malignancies, chronic inflammatory diseases, and immunosuppression, as well as comorbidities and concurrent drugs, were not evaluated in this population. Moreover, although both skin cancer and AD have their peak incidence around 60 years of age, it should be noted that the association between skin cancer and AD has not been well assessed in the adult population.
Although this study adds to the body of supporting evidence for a decreased risk of AD in those with NMSC, it importantly further expands our knowledge with the finding of a decreased risk of Alzheimer's disease in individuals with melanoma. Further exploration of these relationships may help elucidate complex biological and psychosocial interactions between Alzheimer's disease and melanoma and non-melanoma skin cancer. Alzheimer's disease and skin cancer
